- Home
- NRSN vs GDTC Comparison
NRSN vs GDTC Comparison
Compare NRSN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- GDTC
- Stock Information
- Founded
- NRSN 2017
- GDTC 2018
- Country
- NRSN Israel
- GDTC Singapore
- Employees
- NRSN N/A
- GDTC N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- GDTC Health Care
- Exchange
- NRSN Nasdaq
- GDTC Nasdaq
- Market Cap
- NRSN 26.0M
- GDTC 29.4M
- IPO Year
- NRSN 2021
- GDTC 2023
- Fundamental
- Price
- NRSN $0.91
- GDTC $2.20
- Analyst Decision
- NRSN Hold
- GDTC Buy
- Analyst Count
- NRSN 1
- GDTC 1
- Target Price
- NRSN N/A
- GDTC $5.00
- AVG Volume (30 Days)
- NRSN 172.3K
- GDTC 15.6K
- Earning Date
- NRSN 04-08-2025
- GDTC 01-01-0001
- Dividend Yield
- NRSN N/A
- GDTC N/A
- EPS Growth
- NRSN N/A
- GDTC N/A
- EPS
- NRSN N/A
- GDTC N/A
- Revenue
- NRSN N/A
- GDTC $330,254.00
- Revenue This Year
- NRSN N/A
- GDTC $14.71
- Revenue Next Year
- NRSN N/A
- GDTC N/A
- P/E Ratio
- NRSN N/A
- GDTC N/A
- Revenue Growth
- NRSN N/A
- GDTC N/A
- 52 Week Low
- NRSN $0.51
- GDTC $1.20
- 52 Week High
- NRSN $2.25
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- NRSN 29.02
- GDTC 32.65
- Support Level
- NRSN $1.00
- GDTC $1.98
- Resistance Level
- NRSN $1.13
- GDTC $2.56
- Average True Range (ATR)
- NRSN 0.08
- GDTC 0.18
- MACD
- NRSN -0.02
- GDTC -0.05
- Stochastic Oscillator
- NRSN 8.23
- GDTC 27.18
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.